Shares of Ra Pharmaceuticals Inc (NASDAQ:RARX) have been assigned an average broker rating score of 1.00 (Strong Buy) from the three analysts that cover the company, Zacks Investment Research reports. Three analysts have rated the stock with a strong buy recommendation.
Brokerages have set a 1 year consensus target price of $27.67 for the company and are expecting that the company will post ($0.55) earnings per share for the current quarter, according to Zacks. Zacks has also given Ra Pharmaceuticals an industry rank of 97 out of 265 based on the ratings given to its competitors.
RARX has been the topic of several recent analyst reports. BMO Capital Markets upped their target price on Ra Pharmaceuticals from $24.00 to $31.00 and gave the company a “positive” rating in a research report on Tuesday, March 7th. Zacks Investment Research lowered Ra Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, March 10th. Jefferies Group LLC reissued an “in-line” rating and issued a $25.00 price objective on shares of Ra Pharmaceuticals in a report on Tuesday, March 7th. Finally, Credit Suisse Group AG reissued an “outperform” rating and issued a $19.00 price objective on shares of Ra Pharmaceuticals in a report on Tuesday.
Several hedge funds and other institutional investors have recently made changes to their positions in RARX. Teachers Advisors LLC purchased a new position in shares of Ra Pharmaceuticals during the fourth quarter worth $135,000. Fred Alger Management Inc. purchased a new position in shares of Ra Pharmaceuticals during the fourth quarter worth $223,000. Norges Bank purchased a new position in shares of Ra Pharmaceuticals during the fourth quarter worth $304,000. State Street Corp purchased a new position in shares of Ra Pharmaceuticals during the fourth quarter worth $1,060,000. Finally, FIL Ltd purchased a new position in shares of Ra Pharmaceuticals during the fourth quarter worth $1,975,000. 2.55% of the stock is currently owned by institutional investors and hedge funds.
WARNING: This news story was originally posted by Markets Daily and is owned by of Markets Daily. If you are accessing this news story on another publication, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this news story can be read at https://www.themarketsdaily.com/2017/04/21/ra-pharmaceuticals-inc-rarx-given-27-67-average-target-price-by-analysts-updated.html.
Ra Pharmaceuticals (NASDAQ:RARX) traded down 1.86% during trading on Friday, reaching $22.64. The company’s stock had a trading volume of 45,102 shares. The company’s market capitalization is $510.44 million. Ra Pharmaceuticals has a 12-month low of $12.05 and a 12-month high of $24.12. The firm’s 50-day moving average price is $21.65 and its 200 day moving average price is $17.32.
Ra Pharmaceuticals Company Profile
Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ra Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.